Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Quadruple-Negative Breast Cancer: An Uneven Playing Field.

Saini G, Bhattarai S, Gogineni K, Aneja R.

JCO Glob Oncol. 2020 Feb;6:233-237. doi: 10.1200/JGO.19.00366. No abstract available.

PMID:
32073910
2.

A quantitative centrosomal amplification score predicts local recurrence in ductal carcinoma in situ.

Mittal K, Toss MS, Wei G, Kaur J, Choi DH, Melton BD, Osan RM, Milligy IM, Green AR, Janssen EAM, Søiland H, Gogineni K, Manne U, Rida P, Rakha EA, Aneja R.

Clin Cancer Res. 2020 Jan 14. pii: clincanres.1272.2019. doi: 10.1158/1078-0432.CCR-19-1272. [Epub ahead of print]

3.

Intensity-modulated radiation therapy in breast cancer patients following the release of a Choosing Wisely recommendation.

Torres MA, Gogineni K, Howard DH.

J Natl Cancer Inst. 2019 Oct 24. pii: djz198. doi: 10.1093/jnci/djz198. [Epub ahead of print]

PMID:
31647560
4.

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.

Collin LJ, Yan M, Jiang R, Ward KC, Crawford B, Torres MA, Gogineni K, Subhedar PD, Puvanesarajah S, Gaudet MM, McCullough LE.

NPJ Breast Cancer. 2019 Sep 26;5:32. doi: 10.1038/s41523-019-0129-3. eCollection 2019.

5.

Panoptic View of Prognostic Models for Personalized Breast Cancer Management.

Saini G, Mittal K, Rida P, Janssen EAM, Gogineni K, Aneja R.

Cancers (Basel). 2019 Sep 7;11(9). pii: E1325. doi: 10.3390/cancers11091325. Review.

6.

Race differences in cardiovascular disease and breast cancer mortality among US women diagnosed with invasive breast cancer.

Troeschel AN, Liu Y, Collin LJ, Bradshaw PT, Ward KC, Gogineni K, McCullough LE.

Int J Epidemiol. 2019 Dec 1;48(6):1897-1905. doi: 10.1093/ije/dyz108.

PMID:
31155644
7.

The Impact of Genetic Counseling Educational Tools on Patients' Knowledge of Molecular Testing Terminology.

McDaniels BA, Hianik RS, Bellcross C, Shaib WL, Switchenko J, Dixon MD, Meisel JL, Gogineni K, Pentz RD.

J Cancer Educ. 2019 May 7. doi: 10.1007/s13187-019-01535-0. [Epub ahead of print]

PMID:
31062281
8.

US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials.

Regnante JM, Richie NA, Fashoyin-Aje L, Vichnin M, Ford M, Roy UB, Turner K, Hall LL, Gonzalez E, Esnaola N, Clark LT, Adams HC 3rd, Alese OB, Gogineni K, McNeill L, Petereit D, Sargeant I, Dang J, Obasaju C, Highsmith Q, Lee SC, Hoover SC, Williams EL, Chen MS Jr.

J Oncol Pract. 2019 Apr;15(4):e289-e299. doi: 10.1200/JOP.18.00638. Epub 2019 Mar 4.

PMID:
30830833
9.

Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.

Paplomata E, Zelnak A, Santa-Maria CA, Liu Y, Gogineni K, Li X, Moreno CS, Chen Z, Kaklamani V, O'Regan RM.

Clin Breast Cancer. 2019 Jun;19(3):188-196. doi: 10.1016/j.clbc.2018.12.017. Epub 2019 Jan 3.

10.

Obesity and cancer treatment efficacy: Existing challenges and opportunities.

Ross KH, Gogineni K, Subhedar PD, Lin JY, McCullough LE.

Cancer. 2019 May 15;125(10):1588-1592. doi: 10.1002/cncr.31976. Epub 2019 Jan 11. Review. No abstract available.

PMID:
30633328
11.

Cognitive Behavioral Therapy for Insomnia, Mindfulness, and Yoga in Patients With Breast Cancer with Sleep Disturbance: A Literature Review.

Zeichner SB, Zeichner RL, Gogineni K, Shatil S, Ioachimescu O.

Breast Cancer (Auckl). 2017 Dec 7;11:1178223417745564. doi: 10.1177/1178223417745564. eCollection 2017. Review.

12.

Ductal carcinoma in situ: How much is too much?

Gogineni K.

Cancer. 2016 Sep 15;122(18):2780-2. doi: 10.1002/cncr.30107. Epub 2016 May 31. No abstract available.

13.

Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers.

Strauss WM, Carter C, Simmons J, Klem E, Goodman N, Vahidi B, Romero J, Masterman-Smith M, O'Regan R, Gogineni K, Schwartzberg L, Austin LK, Dempsey PW, Cristofanilli M.

Oncotarget. 2016 May 3;7(18):26724-38. doi: 10.18632/oncotarget.8494.

14.

A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer.

Zeichner SB, Terawaki H, Gogineni K.

Breast Cancer (Auckl). 2016 Mar 22;10:25-36. doi: 10.4137/BCBCR.S32783. eCollection 2016. Review.

15.

Patient Demands and Requests for Cancer Tests and Treatments.

Gogineni K, Shuman KL, Chinn D, Gabler NB, Emanuel EJ.

JAMA Oncol. 2015 Apr;1(1):33-9. doi: 10.1001/jamaoncol.2014.197.

PMID:
26182301
16.

The Demanding Patient Revisited--Reply.

Gogineni K, Shuman KL, Gabler NB, Emanuel EJ.

JAMA Oncol. 2015 Jul;1(4):544. doi: 10.1001/jamaoncol.2015.1111. No abstract available.

PMID:
26181272
17.

Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis.

Lester-Coll NH, Lee JM, Gogineni K, Hwang WT, Schwartz JS, Prosnitz RG.

Breast Cancer Res Treat. 2015 Jul;152(1):217-226. doi: 10.1007/s10549-015-3462-8. Epub 2015 Jun 11.

PMID:
26062750
18.

Making cuts to Medicare: the views of patients, physicians, and the public.

Gogineni K, Shuman K, Chinn D, Weber A, Cosenza C, Colten ME, Emanuel EJ.

J Clin Oncol. 2015 Mar 10;33(8):846-53. doi: 10.1200/JCO.2014.56.3262. Epub 2015 Jan 26.

PMID:
25624440
19.

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.

DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P.

Clin Cancer Res. 2015 Mar 1;21(5):995-1001. doi: 10.1158/1078-0432.CCR-14-2258. Epub 2014 Dec 11.

20.

Survey of oncologists about shortages of cancer drugs.

Gogineni K, Shuman KL, Emanuel EJ.

N Engl J Med. 2013 Dec 19;369(25):2463-4. doi: 10.1056/NEJMc1307379. No abstract available.

PMID:
24350971

Supplemental Content

Loading ...
Support Center